Sanofi Return on Tangible Equity 2010-2023 | SNY
Current and historical return on tangible equity values for Sanofi (SNY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Sanofi Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-12-31 |
$5.84B |
$0.68B |
-8230.99% |
| 2023-09-30 |
$9.68B |
|
1359.27% |
| 2023-06-30 |
$9.02B |
$-0.97B |
1266.99% |
| 2023-03-31 |
$8.71B |
|
1389.62% |
| 2022-12-31 |
$8.82B |
$3.81B |
1407.82% |
| 2022-09-30 |
$8.33B |
|
-2546.79% |
| 2022-06-30 |
$8.13B |
$-1.31B |
-2484.71% |
| 2022-03-31 |
$9.16B |
|
inf% |
| 2021-09-30 |
$8.76B |
|
inf% |
| 2021-03-31 |
$7.99B |
|
inf% |
| 2020-09-30 |
$7.39B |
|
inf% |
| 2020-03-31 |
$6.36B |
|
inf% |
| 2019-09-30 |
$4.98B |
|
358.59% |
| 2019-03-31 |
$4.86B |
|
349.80% |
| 2018-03-31 |
$4.71B |
|
213.20% |
| 2017-12-31 |
$9.53B |
$5.55B |
431.84% |
| 2017-09-30 |
$9.90B |
|
375.74% |
| 2017-06-30 |
$9.92B |
$3.28B |
376.72% |
| 2017-03-31 |
$10.09B |
|
348.25% |
| 2016-12-31 |
$5.21B |
$7.26B |
179.89% |
| 2016-09-30 |
$6.19B |
|
571.45% |
| 2016-06-30 |
$5.76B |
$4.33B |
370.05% |
| 2016-03-31 |
$5.52B |
|
1092.28% |
| 2015-09-30 |
$4.90B |
|
1126.39% |
| 2015-06-30 |
$4.59B |
$1.89B |
-380.60% |
| 2014-06-30 |
$5.57B |
$0.13B |
-331.30% |
| 2013-06-30 |
$6.39B |
$-0.28B |
-179.04% |
| 2012-06-30 |
$8.61B |
$-6.56B |
-246.22% |
| 2012-03-31 |
$8.56B |
|
-188.25% |
| 2011-12-31 |
$9.33B |
$-7.42B |
-205.26% |
| 2011-09-30 |
$8.04B |
|
3127.63% |
| 2011-06-30 |
$7.45B |
$-10.76B |
2900.39% |
| 2011-03-31 |
$8.22B |
|
180.72% |
| 2010-12-31 |
$8.24B |
$11.79B |
181.09% |
| 2010-09-30 |
$9.30B |
|
279.03% |
| 2010-06-30 |
$10.37B |
$6.41B |
311.16% |
| 2010-03-31 |
$11.38B |
|
634.37% |
| 2009-12-31 |
$10.99B |
$6.93B |
612.79% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$116.640B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
